Inhibition of cholinergic, neurogenic, and non-cholinergic/non-neurogenic detrusor contractions by the Rac inhibitor EHT1864

Inhibition of cholinergic, neurogenic, and non-cholinergic/non-neurogenic detrusor contractions by the Rac inhibitor EHT1864

Bibliographic Details
Main Authors:	B. Li, Q. Yu, X. Wang, A. Tamalunas, R. Waidelich, C.G. Stief, C. Gratzke, M. Hennenberg
Format:	Article
Language:	English
Published:	Elsevier 2020-07-01
Series:	European Urology Open Science
Online Access:	http://www.sciencedirect.com/science/article/pii/S2666168320327373

Similar Items

Inhibition of Female and Male Human Detrusor Smooth Muscle Contraction by the Rac Inhibitors EHT1864 and NSC23766
by: Bingsheng Li, et al.
Published: (2020-04-01)

Rac1 inhibition by EHT1864, NSC23766 or by knockdown of Rac1 expression reduces proliferation and contraction of human bladder smooth muscle cells
by: R. Wang, et al.
Published: (2020-07-01)

The STK-16 inhibitor STK16-IN-1 inhibits non-neurogenic/non-adrenergic smooth muscle contractions in the human prostate and the human male detrusor
by: B. Li, et al.
Published: (2020-07-01)

Concentration-dependent alpha1-Adrenoceptor Antagonism and Inhibition of Neurogenic Smooth Muscle Contraction by Mirabegron in the Human Prostate
by: Ru Huang, et al.
Published: (2021-06-01)

Botulinum Toxin in Neurogenic Detrusor Overactivity
by: Carlos Arturo Levi D'Ancona, et al.
Published: (2012-09-01)

Characterization of the widely used Rac1-inhibitors NSC23766 and EHT1864 in mouse platelets
by: Heidenreich, Julius Frederik
Published: (2018)

Molecular mechanisms involved in neurogenic detrusor overactivity
by: João Paulo Garrido Vieira dos Santos
Published: (2019)

Neurogenic abnormalities in Alzheimer's disease differ between stages of neurogenesis and are partly related to cholinergic pathology
by: Elaine K. Perry, et al.
Published: (2012-08-01)

The Botulinum Treatment of Neurogenic Detrusor Overactivity: The Double-Face of the Neurotoxin
by: Chiara Traini, et al.
Published: (2019-10-01)

Detrusor Arreflexia as an End Stage of Neurogenic Bladder in HAM/TSP?
by: Matheus Tannus, et al.
Published: (2011-01-01)

Botulinum Toxin-A Therapy in Pediatric Urology: Indications for the Neurogenic and Non-Neurogenic Neurogenic Bladder
by: Lori Dyer, et al.
Published: (2009-01-01)

Neurogenic and non neurogenic functions of endogenous neural stem cells.
by: Erica eButti, et al.
Published: (2014-04-01)

Inhibition of human prostate smooth muscle contraction by thalidomide: A novel remedy in LUTS?
by: A. Tamalunas, et al.
Published: (2020-07-01)

The Successful and Novel Treatment of Non-Neurogenic Detrusor-External Sphincter Dyssynergia (DESD) with Botulinum Toxin A
by: Tricia LC Kuo MBBS, MRCSEd, M Med (Surg), FAMS, et al.
Published: (2013-06-01)

Experience with different botulinum toxins for the treatment of refractory neurogenic detrusor overactivity
by: Cristiano M. Gomes, et al.
Published: (2010-02-01)

Effect of botulinum toxin type A on idiopathic and neurogenic detrusor overactivity
by: Jurij Leskovar, et al.
Published: (2010-06-01)

Inosine Improves Neurogenic Detrusor Overactivity following Spinal Cord Injury.
by: Yeun Goo Chung, et al.
Published: (2015-01-01)

Pharmacokinetics of solifenacin in pediatric populations with overactive bladder or neurogenic detrusor overactivity
by: Stacey Tannenbaum, et al.
Published: (2020-12-01)

Inhibition of human prostate smooth muscle contraction by the integrin α2β1-selective inhibitor BTT3033 and the integrin-linked kinase inhibitor Cpd22
by: B. Li, et al.
Published: (2020-07-01)

OnabotulinumtoxinA for neurogenic detrusor overactivity and dose differences: a systematic review
by: Rui Zhang, et al.
Published: (2015-04-01)

Sphingosine Kinase 1 urothelial expression is increased in patients with neurogenic detrusor overactivity
by: Quentin Ballouhey, et al.
Published: (2015-12-01)

Botulinum toxin A for the treatment of neurogenic detrusor overactivity in multiple sclerosis patients
by: S. Deffontaines-Rufin, et al.
Published: (2011-10-01)

Experience with botulinum toxin type A in the treatment of neurogenic detrusor overactivity in clinical practice
by: Stephanie Knuepfer, et al.
Published: (2014-02-01)

Efficacy and safety of propiverine in cpomparison to oxybutynin in children with neurogenic detrusor overactivity: an observational study
by: Schulte-Baukloh H, et al.
Published: (2005-12-01)

Oxybutynin and tolterodine for treatment of neurogenic detrusor overactivity: a pharmacoeconomic evaluation in the Brazilian context
by: Rodrigo Silva Suguino, et al.
Published: (2012-06-01)

Contractile and Structural Properties of Detrusor from Children with Neurogenic Lower Urinary Tract Dysfunction
by: Navroop Johal, et al.
Published: (2021-09-01)

Clinical outcomes of botulinum toxin A management for neurogenic detrusor overactivity: meta-analysis
by: Shang-Jun Wu, et al.
Published: (2019-01-01)

The use and rationale of selective alpha blockade in children with non-neurogenic neurogenic bladder dysfunction
by: Guy Bogaert, et al.
Published: (2004-04-01)

Microglia from neurogenic and non-neurogenic regions display differential proliferative potential and neuroblast support
by: Gregory Paul Marshall, et al.
Published: (2014-07-01)

Management of Neurogenic Detrusor Overactivity Caused by Spinal Cord Injury - The Case of Botulinum Toxin and Resiniferatoxin
by: Raquel Leal Monteiro Mano de Oliveira
Published: (2020)

Intravesical electromotive botulinum toxin-A administration: Will it be the standard treatment for refractory neurogenic detrusor overactivity?
by: Neeraj Kumar Goyal, et al.
Published: (2011-01-01)

Botulinum toxin A in the treatment of spinal cord injury patients with refractory neurogenic detrusor overactivity
by: Ronaldo A. Alvares, et al.
Published: (2010-12-01)

Therapeutic outcome and patient adherence to repeated onabotulinumtoxinA detrusor injections in chronic spinal cord-injured patients and neurogenic detrusor overactivity
by: Sheng-Fu Chen, et al.
Published: (2015-07-01)

Calcium channel subtypes for cholinergic and non-adrenergic non-cholinergic neurotransmission in the isolated guinea-pig trachea
by: Shih Chih-Hsien, et al.
Published: (1998)

What are useful signs to differentiate detrusor underactivity from bladder outlet obstruction in men with non-neurogenic lower urinary tract symptoms?
by: Y. Matsukawa, et al.
Published: (2020-07-01)

Discerning neurogenic vs. non-neurogenic postnatal lateral ventricular astrocytes via activity-dependent input
by: Elena W. Adlaf, et al.
Published: (2016-03-01)

Outcomes of non-surgical interventions for neurogenic claudication
by: Comer, Christine
Published: (2011)

Efficacy and Safety of OnabotulinumtoxinA in Treating Neurogenic Detrusor Overactivity: A Systematic Review and Meta-analysis
by: Xin Zhou, et al.
Published: (2015-01-01)

A foreseeable tissue engineering approach to overcome the neurogenic bladder-related detrusor/urethral rhabdosphincter dyssynergia
by: Contardo eAlberti
Published: (2014-11-01)

OnabotulinumtoxinA treatment for neurogenic detrusor overactivity and the prevention of autonomic dysreflexia following spinal cord injury
by: Fougere, Renée Julia
Published: (2014)